JP2014111643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014111643A5 JP2014111643A5 JP2014026425A JP2014026425A JP2014111643A5 JP 2014111643 A5 JP2014111643 A5 JP 2014111643A5 JP 2014026425 A JP2014026425 A JP 2014026425A JP 2014026425 A JP2014026425 A JP 2014026425A JP 2014111643 A5 JP2014111643 A5 JP 2014111643A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- independently
- composition according
- absent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 25
- 206010061218 Inflammation Diseases 0.000 claims 11
- 230000004054 inflammatory process Effects 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 150000004665 fatty acids Chemical class 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010049565 Muscle fatigue Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 3
- 150000003873 salicylate salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023514 Barrett esophagus Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000009326 ileitis Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000013256 infectious meningitis Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000006014 omega-3 oil Substances 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 claims 1
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 claims 1
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 claims 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 1
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical class CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical class NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- KBGYPXOSNDMZRV-PDBXOOCHSA-N all-cis-7,10,13-hexadecatrienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCC(O)=O KBGYPXOSNDMZRV-PDBXOOCHSA-N 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical class C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- MAMJNXVNGGBHFN-UHFFFAOYSA-N docosa-1,3,5,7,9,11-hexaene Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC=C MAMJNXVNGGBHFN-UHFFFAOYSA-N 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 1
- 230000007071 enzymatic hydrolysis Effects 0.000 claims 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 1
- 229960002268 triflusal Drugs 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7898308P | 2008-07-08 | 2008-07-08 | |
| US61/078,983 | 2008-07-08 | ||
| US10436608P | 2008-10-10 | 2008-10-10 | |
| US10436308P | 2008-10-10 | 2008-10-10 | |
| US10436408P | 2008-10-10 | 2008-10-10 | |
| US61/104,363 | 2008-10-10 | ||
| US61/104,364 | 2008-10-10 | ||
| US61/104,366 | 2008-10-10 | ||
| US14865809P | 2009-01-30 | 2009-01-30 | |
| US61/148,658 | 2009-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517582A Division JP5688015B2 (ja) | 2008-07-08 | 2009-07-08 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014111643A JP2014111643A (ja) | 2014-06-19 |
| JP2014111643A5 true JP2014111643A5 (enExample) | 2014-08-07 |
| JP5901669B2 JP5901669B2 (ja) | 2016-04-13 |
Family
ID=41114866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517582A Expired - Fee Related JP5688015B2 (ja) | 2008-07-08 | 2009-07-08 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
| JP2014026425A Expired - Fee Related JP5901669B2 (ja) | 2008-07-08 | 2014-02-14 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517582A Expired - Fee Related JP5688015B2 (ja) | 2008-07-08 | 2009-07-08 | 脂肪酸でアセチル化されたサリチレート及びその使用 |
Country Status (32)
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5337479B2 (ja) | 2005-05-04 | 2013-11-06 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 新規化合物 |
| US8399516B2 (en) | 2006-11-01 | 2013-03-19 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) |
| WO2009061208A1 (en) | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| KR101783817B1 (ko) | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| DK2473045T3 (en) | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
| USRE46608E1 (en) | 2009-09-01 | 2017-11-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| TW201138832A (en) * | 2010-01-20 | 2011-11-16 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
| WO2011106688A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
| US9216224B2 (en) | 2010-03-05 | 2015-12-22 | Catabasis Pharmaceuticals, Inc. | Fatty acid COX inhibitor derivatives and their uses |
| EP2569015A1 (en) | 2010-05-14 | 2013-03-20 | Iberhospitex S.A. | Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers |
| SG10201509127YA (en) | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| BR112013015604B1 (pt) | 2010-12-22 | 2021-11-03 | D. Western Therapeutics Institute, Inc | Derivado de isoquinolina-6-sulfonamida, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou prevenir glaucoma, hipertensão ocular ou doença cardiovascular |
| EP2949344A3 (en) | 2011-03-18 | 2016-01-13 | Catabasis Pharmaceuticals, Inc. | Use of intracellular enzymes for the release of covalently linked bioactives |
| WO2012154564A1 (en) * | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid phenolic derivatives and their uses |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| JP5977355B2 (ja) * | 2011-09-29 | 2016-08-24 | エコール ノルマル シュペリウール ドゥ リヨン | ペプチダーゼの蛍光発生基質 |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| JP2015522531A (ja) * | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| AU2013264896A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| WO2013177536A2 (en) | 2012-05-25 | 2013-11-28 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2014004951A1 (en) * | 2012-06-28 | 2014-01-03 | Kean University | Novel fatty acid-salicylate conjugates with enhanced therapeutic properties |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| WO2014115098A1 (en) * | 2013-01-26 | 2014-07-31 | Mahesh Kandula | Compositions and methods for the treatment of neurological diseases and inflammation |
| US11351139B2 (en) | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP2889286B1 (en) * | 2013-12-30 | 2016-05-18 | Pax Forschung GmbH | Pharmaceutically active compound for use as anti-inflammatory agent |
| EP3116469B1 (en) | 2014-03-10 | 2018-10-03 | Mary Kay, Inc. | Skin lightening compositions |
| KR20170051414A (ko) * | 2014-07-18 | 2017-05-11 | 바이오코젠트, 엘엘씨 | 살리실레이트 및 폴리살리실레이트를 포함하는 조성물 및 방법 |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
| CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| CN107207411A (zh) | 2014-12-01 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| ES2905771T3 (es) | 2015-01-06 | 2022-04-12 | Cellix Bio Private Ltd | Composiciones y procedimientos para el tratamiento de la inflamación y del dolor |
| AU2016256552B2 (en) | 2015-04-28 | 2021-04-01 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| WO2016178066A1 (en) * | 2015-05-01 | 2016-11-10 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| WO2018029545A1 (en) * | 2016-08-11 | 2018-02-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of irritable bowel syndrome |
| WO2018067847A1 (en) * | 2016-10-05 | 2018-04-12 | Baylor College Of Medicine | Structure of gii.4 norovirus protease -design of broad-spectrum protease inhibitors |
| US12503426B2 (en) | 2017-09-01 | 2025-12-23 | Lipovexa Srl | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof |
| JP2020536058A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019090271A1 (en) * | 2017-11-06 | 2019-05-09 | Catabasis Pharmaceuticals, Inc. | Edasalonexent dosing regimen for treating muscular dystrophy |
| JP2021503474A (ja) * | 2017-11-17 | 2021-02-12 | 浙江越甲▲薬▼▲業▼有限公司 | 局所麻酔薬 |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| WO2020191087A1 (en) | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
| CN114853627B (zh) * | 2022-04-26 | 2023-06-20 | 自然资源部第三海洋研究所 | 一种取代苯甲酸二十二碳六烯酰胺乙基酯衍生物及其制备方法与应用 |
| CN114853628B (zh) * | 2022-05-07 | 2023-10-13 | 自然资源部第三海洋研究所 | 一种二十二碳六烯酰酯衍生物及其制备方法和应用 |
| CN119504664B (zh) * | 2025-01-17 | 2025-06-24 | 广东医科大学附属医院 | 二十碳五烯酸衍生物及其制备方法和应用、防治神经系统疾病药物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036951A (en) * | 1973-03-12 | 1977-07-19 | Synergistics, Inc. | Ultra-violet filtration with certain aminosalicylic acid esters |
| ES428254A1 (es) | 1974-07-15 | 1976-08-16 | Inst Internacional Terapeutico | Procedimiento para la obtencion de 2-acetoxibenzoatos de n-(2-hidroxietil) amidas de acidos grasos. |
| US4199576A (en) | 1976-12-15 | 1980-04-22 | The Procter & Gamble Company | Analgesic and anti-inflammatory compositions for topical application |
| US4276430A (en) | 1976-12-15 | 1981-06-30 | The Procter & Gamble Company | Analgesic and anti-inflammatory compounds and compositions containing same |
| CA1113486A (en) | 1977-04-01 | 1981-12-01 | Alfred Halpern | Ultra-violet filtration with certain aminosalicylic acid esters |
| US4204517A (en) * | 1978-03-30 | 1980-05-27 | Rumsey Joseph N | Fireplace furnace |
| US4264517A (en) * | 1978-12-11 | 1981-04-28 | G.D. Searle & Co. | Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates |
| US4551279A (en) | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
| IT1196348B (it) * | 1984-11-29 | 1988-11-16 | Italfarmaco Spa | Composti ad attivita'antiinfiammatoria |
| JPS62223159A (ja) | 1986-03-25 | 1987-10-01 | Ono Pharmaceut Co Ltd | （ｎ−置換フエニル）不飽和脂肪酸アミド誘導体、それらの製造方法及びそれらを有効成分として含有する５−リポキシゲナ−ゼ阻害剤 |
| US4670465A (en) * | 1986-05-21 | 1987-06-02 | Syntex (U.S.A.) Inc. | Arachidonic acid analogs |
| US5760261A (en) * | 1990-02-28 | 1998-06-02 | Guttag; Alvin | Higher fatty acid derivatives of salicylic acid and salts thereof |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| CA2167818A1 (en) | 1993-08-02 | 1995-02-09 | Robert George Whittaker | Therapeutic compound - fatty acid conjugates |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| GB9508023D0 (en) * | 1995-04-20 | 1995-06-07 | Scotia Holdings Plc | Fatty acid derivatives |
| CA2220091C (en) | 1995-05-01 | 2011-01-04 | Scotia Holdings Plc | Nicotinic acid esters and pharmaceutical compositions containing them |
| USRE40546E1 (en) | 1996-05-01 | 2008-10-21 | Scarista, Ltd. | 1,3-Propane diol esters and ethers and methods for their use in drug delivery |
| CN1187813A (zh) * | 1995-05-01 | 1998-07-15 | 斯科舍集团有限公司 | 作为生物活性化合物的脂肪酸酯 |
| MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| GB9622636D0 (en) | 1996-10-30 | 1997-01-08 | Scotia Holdings Plc | Presentation of bioactives |
| US5728732A (en) | 1996-11-27 | 1998-03-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters and retinoids |
| EP1153049B1 (en) | 1999-01-29 | 2005-08-10 | Amersham Biosciences KK | Temperature-responsive polymer compound and process for producing the same |
| GB9930026D0 (en) * | 1999-12-21 | 2000-02-09 | Univ Sheffield | Novel compounds of unsaturated fatty acids |
| US6387945B2 (en) | 2000-04-11 | 2002-05-14 | The Regents Of The University Of California | Lipoic acid analogs |
| KR100939243B1 (ko) | 2001-01-19 | 2010-01-29 | 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 | 포타슘 채널의 기능을 조절하는 아민 유도체, 그의제조방법 및 용도 |
| US6821529B2 (en) | 2001-09-05 | 2004-11-23 | Deanna Jean Nelson | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
| JP4321174B2 (ja) | 2002-10-24 | 2009-08-26 | ソニー株式会社 | 可逆性多色記録媒体、及びこれを用いた記録方法 |
| US20040254357A1 (en) * | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
| WO2006066894A1 (en) | 2004-12-24 | 2006-06-29 | Ctg Pharma S.R.L. | Compounds for treating metabolic syndrome |
| US20070155747A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2007116027A1 (en) | 2006-04-12 | 2007-10-18 | Unilever Plc | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
| CN102088965B (zh) | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
| US8946451B2 (en) | 2009-10-05 | 2015-02-03 | Catabasis Pharmaceuticals, Inc. | Lipoic acid acylated salicylate derivatives and their uses |
| WO2011044140A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Substituted thioacetic acid salicylate derivatives and their uses |
| TW201138832A (en) | 2010-01-20 | 2011-11-16 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
| WO2012003563A1 (pt) | 2010-07-07 | 2012-01-12 | Universidade Federal De Minas Gerais - Ufmg | Composições farmacêuticas antineoplásicas contendo compostos nitroaromáticos substituídos |
| EP2949344A3 (en) | 2011-03-18 | 2016-01-13 | Catabasis Pharmaceuticals, Inc. | Use of intracellular enzymes for the release of covalently linked bioactives |
| EP2701509A4 (en) | 2011-04-29 | 2015-06-17 | Catabasis Pharmaceuticals Inc | Fatty Acid Guanidine and SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES |
| US20130059801A1 (en) | 2011-08-31 | 2013-03-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid amides, compositions and methods of use |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
-
2009
- 2009-07-08 DK DK09790168.0T patent/DK2315740T3/en active
- 2009-07-08 CA CA2729186A patent/CA2729186C/en not_active Expired - Fee Related
- 2009-07-08 ES ES14176625.3T patent/ES2656903T3/es active Active
- 2009-07-08 EP EP14176625.3A patent/EP2813486B1/en not_active Not-in-force
- 2009-07-08 LT LTEP09790168.0T patent/LT2315740T/lt unknown
- 2009-07-08 PL PL09790168T patent/PL2315740T3/pl unknown
- 2009-07-08 KR KR1020117002838A patent/KR101708065B1/ko not_active Expired - Fee Related
- 2009-07-08 SI SI200931789T patent/SI2315740T1/en unknown
- 2009-07-08 PT PT97901680T patent/PT2315740T/pt unknown
- 2009-07-08 MY MYPI20110034 patent/MY151987A/en unknown
- 2009-07-08 ES ES09790168.0T patent/ES2656793T3/es active Active
- 2009-07-08 WO PCT/US2009/049982 patent/WO2010006085A1/en not_active Ceased
- 2009-07-08 SM SM20180035T patent/SMT201800035T1/it unknown
- 2009-07-08 US US12/499,779 patent/US8173831B2/en not_active Expired - Fee Related
- 2009-07-08 BR BRPI0915536A patent/BRPI0915536A2/pt not_active Application Discontinuation
- 2009-07-08 NZ NZ590179A patent/NZ590179A/xx not_active IP Right Cessation
- 2009-07-08 NZ NZ601932A patent/NZ601932A/en not_active IP Right Cessation
- 2009-07-08 HU HUE09790168A patent/HUE035896T2/en unknown
- 2009-07-08 CN CN201410254305.5A patent/CN104000808A/zh active Pending
- 2009-07-08 MX MX2011000273A patent/MX2011000273A/es active IP Right Grant
- 2009-07-08 AU AU2009268610A patent/AU2009268610C1/en not_active Ceased
- 2009-07-08 EP EP09790168.0A patent/EP2315740B1/en active Active
- 2009-07-08 HR HRP20180107TT patent/HRP20180107T1/hr unknown
- 2009-07-08 CN CN200980135113.XA patent/CN102149673B/zh not_active Expired - Fee Related
- 2009-07-08 NO NO09790168A patent/NO2315740T3/no unknown
- 2009-07-08 SG SG2013052717A patent/SG192488A1/en unknown
- 2009-07-08 JP JP2011517582A patent/JP5688015B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-28 IL IL210318A patent/IL210318A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00179A patent/ZA201100179B/en unknown
- 2011-01-06 EC EC2011010746A patent/ECSP11010746A/es unknown
- 2011-01-06 CO CO11001289A patent/CO6341615A2/es active IP Right Grant
- 2011-01-07 SV SV2011003798A patent/SV2011003798A/es unknown
- 2011-01-07 NI NI201100013A patent/NI201100013A/es unknown
- 2011-01-07 GT GT201100006A patent/GT201100006A/es unknown
-
2012
- 2012-03-22 US US13/427,639 patent/US8735378B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,644 patent/US8729293B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,650 patent/US8735379B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,654 patent/US9139516B2/en not_active Expired - Fee Related
-
2013
- 2013-06-20 PH PH12013501319A patent/PH12013501319A1/en unknown
-
2014
- 2014-02-14 JP JP2014026425A patent/JP5901669B2/ja not_active Expired - Fee Related
- 2014-04-11 US US14/251,257 patent/US9272984B2/en not_active Expired - Fee Related
- 2014-04-11 US US14/251,247 patent/US9458094B2/en not_active Expired - Fee Related
-
2016
- 2016-10-03 US US15/283,995 patent/US20170246193A1/en not_active Abandoned
-
2017
- 2017-12-12 US US15/839,346 patent/US20180325923A1/en not_active Abandoned
-
2018
- 2018-01-08 CY CY20181100018T patent/CY1119784T1/el unknown
-
2019
- 2019-03-14 US US16/353,575 patent/US20200046738A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,334 patent/US20210169905A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599067A (en) | Fatty acid niacin conjugates and their uses | |
| JP2011527691A5 (enExample) | ||
| HRP20200065T1 (hr) | Upotreba etilnog estera ikozapentaenske kiseline u liječenju hipertrigliceridemije | |
| NZ601932A (en) | Fatty acid acetylated salicylates and their uses | |
| NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| JP2013510885A5 (enExample) | ||
| WO2013090420A3 (en) | Fatty acid antiviral conjugates and their uses | |
| JP2017526623A5 (enExample) | ||
| JP2016538254A5 (enExample) | ||
| NZ626699A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| JP2013521310A5 (enExample) | ||
| JP2020500193A5 (enExample) | ||
| JP2012067115A5 (enExample) | ||
| JP2012526094A5 (enExample) | ||
| HRP20150167T4 (hr) | Spojevi kao antagonisti bradikinina-b1 | |
| JP2011529503A5 (enExample) | ||
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| JP7368354B2 (ja) | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 | |
| JP2009530398A5 (enExample) | ||
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| HRP20140277T1 (hr) | Kompozicija za lijeäśenje cistiäśne fibroze | |
| JP2014518609A5 (enExample) | ||
| JP2003508484A5 (enExample) | ||
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение |